Compare Mattel Inc (MAT) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mattel Inc vs Moderna, Inc. — how do they compare? Mattel Inc trades at $16.81 (market cap $4.74B), while Moderna, Inc. trades at $204.19 (market cap $78.65B). The key difference: Moderna, Inc. is far larger — about 16.6× Mattel Inc's market cap, and Moderna, Inc. is trading nearer its 52-week high, Mattel Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Mattel Inc for 97 Days and Moderna, Inc. for 59 Days on average.
| MAT | MRNA | |
|---|---|---|
Market Cap | $4.74B | $78.65B |
Volume | 11,809,722 | 37,373,437 |
Sector | Consumer Cyclical | Health |
52-Week High | $22.16 | $203.46 |
52-Week Low | $12.66 | $22.36 |
Typical Hold Time | 97 Days | 59 Days |
Enterprise Value | $6.96B | $74.80B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Mattel (MAT) trades at $16.37, up 2.76% on the day, with a bullish technical signal and strong profitability metrics including a 20.5% ROE and 7.78% net margin. Recent news highlights takeover interest from Authentic Brands Group and a CEO transition to Roger Lynch. Cash flow turned negative in 2025 at -$145M, but revenue remains stable around $5.3B.
The stock presents a mixed outlook: analyst consensus is a Buy with a $15.00 price target, but recent earnings misses and negative cash flow pose risks. Upside is supported by takeover speculation and solid brand portfolio, while execution under new leadership and Barbie sales trends are key watchpoints.
Moderna (MRNA) trades at $196.48, up 4.81% with strong technical momentum as it joins the Nasdaq-100 index. Despite recent earnings beats, the company faces fundamental challenges with revenue declining from $18.9B in 2022 to $1.92B in 2025 and negative net income margins exceeding -140%. The stock's 500% rally in 2026 has pushed valuations to elevated levels with P/S ratio of 35.08, creating divergence between technical strength and financial fundamentals.
While Nasdaq inclusion and cancer vaccine pipeline progress offer catalysts, Moderna faces significant execution risks amid declining COVID revenue and high valuation multiples. Analyst consensus remains cautious with only 28% buy ratings and $115.70 price target well below current levels, suggesting limited near-term upside despite technical bullish signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mattel Inc
Mattel markets toy products that are sold to its wholesale customers and direct to retail consumers. The company offers products for children and families, including toys for infants and preschoolers, girls and boys, youth electronics, handheld and other games, puzzles, educational toys, media-driven products, and plush and fashion-related toys. Mattel's owned portfolio includes Barbie, Hot Wheels, Fisher-Price, Thomas & Friends, and American Girl. In addition, it currently manufactures toy products for its segments both internally and externally (through manufacturing partners). Just over half of its net sales are in North America, while the remainder stem from international markets.
Read more on MAT →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
